Bronchopulmonary Dysplasia - Market Insight, Epidemiology and Market Forecast - 2032

This ‘Bronchopulmonary Dysplasia-Market Insights, Epidemiology, and Market Forecast-2032' report deliver an in-depth understanding of the Bronchopulmonary Dysplasia, historical and forecasted epidemiology as well as the Bronchopulmonary Dysplasia market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

The Bronchopulmonary Dysplasia market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted 7MM Bronchopulmonary Dysplasia market size from 2019 to 2032. The Report also covers current Bronchopulmonary Dysplasia treatment practice, market drivers, market barriers, SWOT analysis, reimbursement, market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019-2032

Bronchopulmonary Dysplasia Disease Understanding and Treatment Algorithm

Bronchopulmonary Dysplasia Overview

Bronchopulmonary dysplasia (Bronchopulmonary Dysplasia) is a chronic respiratory disease that often occurs in low-weight or premature infants who have received supplemental oxygen or have spent long periods on a breathing machine (mechanical ventilation), such as infants with acute respiratory distress syndrome. Bronchopulmonary Dysplasia also occurs in older infants who experience abnormal lung development or those that have an antenatal infection or placental abnormalities (like preeclampsia) or chorioamnionitis. Babies are not born with Bronchopulmonary Dysplasia, also referred to as chronic lung disease of prematurity, it is associated with how a baby's lung tissue develops.

The risk of developing Bronchopulmonary Dysplasia increases the earlier a baby is born and the lower the birth weight. Affected infants have rapid, labored breathing, tachypnea, cyanosis, feeding difficulties, and recurrent lung infection. The pathogenesis of Bronchopulmonary Dysplasia remains complex and poorly understood. It results from various factors that injure small airways and can interfere with alveolarization, leading to alveolar simplification with a reduction in the overall surface area for gas exchange. The developing pulmonary microvasculature is also injured. Damage to the lung during a critical stage of lung growth results in clinically significant pulmonary dysfunction
Bronchopulmonary Dysplasia is divided into three severity grades (mild, moderate, or severe) based on respiratory support needs at 36 weeks postmenstrual age (PMA). The exact, underlying mechanisms that cause classic or new Bronchopulmonary Dysplasia are complex and not fully understood. The causes of Bronchopulmonary Dysplasia in one infant may be different from the causes in another. Most likely, multiple different environmental and genetic factors all play a role in the development of the disorder.

The cases of Bronchopulmonary Dysplasia have been increasing, most likely because of modern advances in medicine, which have enabled doctors to keep more low birth weight, premature babies alive than in the past.

Bronchopulmonary Dysplasia Diagnosis

Infants with Bronchopulmonary Dysplasia show substantial heterogeneity in clinical presentation and long-term outcomes. The manner and precision with which Bronchopulmonary Dysplasia is defined have far-reaching consequences for translational and clinical research.

Diagnosis is done based upon identification of characteristic symptoms, detailed patient history, thorough clinical evaluation, and a variety of specialized tests, including blood tests, chest x-rays, and echocardiograms. Many infants now, diagnosed with Bronchopulmonary Dysplasia, are born at an earlier gestational age than before. These cases are sometimes referred to as “new Bronchopulmonary Dysplasia.” They generally have less inflammation and scarring than classic Bronchopulmonary Dysplasia.

Bronchopulmonary Dysplasia Treatment

To date, there is no specific cure for Bronchopulmonary Dysplasia, and the focus is on minimizing lung damage and providing support for the lung to heal and grow. Treatment includes mechanical ventilation along with supplemental oxygen to improve lung capacity and help them breathe. Antenatal steroid treatment before preterm birth and early treatment with surfactant reduce the need for high levels of respiratory support after birth. Infants are also given different medications, including bronchodilators, diuretics, antibiotics, and steroids to reduce lung inflammation and congestion. Proper nutrition management ensures healthy lung development.

Current strategies for the prevention of Bronchopulmonary Dysplasia can broadly be divided into antenatal pharmacologic interventions such as maternal progesterone and antenatal steroids and postnatal pharmacologic interventions.

Though Bronchopulmonary Dysplasia management has improved with the advent of new and effective perinatal strategies, it still is the most common complication associated with prematurity and the major cause of respiratory morbidities. Its prevention and management remain a major challenge for neonatologists, especially with the increasing survival of extremely premature infants.

Bronchopulmonary Dysplasia Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total incident cases of Bronchopulmonary Dysplasia, weight-specific cases of bronchopulmonary dysplasia, severity-specific cases of bronchopulmonary dysplasia scenario of Bronchopulmonary Dysplasia in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2019 to 2032.

Key Findings

• Total incident cases of Bronchopulmonary Dysplasia in the 7MM were found to be 17,058 in 2021. These cases are expected to increase by 2032 at a CAGR of 0.5% during the study period (2019-2032). The incident cases of BPD are derived from preterm population of < 28 weeks.
• Among 7MM, the United States has the highest incident cases of Bronchopulmonary Dysplasia with 13,222 cases in 2021.
• Assessments as per the analysts show that the majority of cases of Bronchopulmonary Dysplasia are in ≤750 g birth weight preterm infants as compared to other birth-weight groups. In the United States, there were 5,203 cases of Bronchopulmonary Dysplasia in ≤750 g birth weight group preterm infants followed by 751-1000 g (5,022 cases), 1001-1250 g (2,290 cases), and ≥1250 g (706 cases) in 2021. These cases are expected to increase by 2032.
• The severity‐specific data reveal the highest number of preterm infants are having mild Bronchopulmonary Dysplasia.
• In the United States, there were a total of 5,210, 5,192, and 2,820 severity-specific cases of mild, moderate, and severe Bronchopulmonary Dysplasia respectively, in 2021. As per the analysts, the severity-specific cases of Bronchopulmonary Dysplasia will increase by 2032.
• In EU-5, Germany has the highest number of cases of Bronchopulmonary Dysplasia with 944 cases in 2021, followed by France with 931 cases and the United Kingdom with 735 cases. While Italy has the least number of cases with 386 in 2021.
• In 2021, Japan had 452 incident cases of Bronchopulmonary Dysplasia.

Bronchopulmonary Dysplasia Epidemiology

The epidemiology segment also provides the Bronchopulmonary Dysplasia epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Bronchopulmonary Dysplasia Drug Chapters

The drug chapter segment of the Bronchopulmonary Dysplasia report encloses the detailed analysis of Bronchopulmonary Dysplasia marketed drugs, mid-phase, and late-stage pipeline drugs. It also helps to understand the Bronchopulmonary Dysplasia clinical trial details, expressive pharmacological action, agreements and collaborations, approval, and patent details of each included drug, and the latest news and press releases.

Bronchopulmonary Dysplasia Emerging Drugs

OHB-607: Takeda/Oak Hill Bio

Oak Hill's lead therapeutic candidate, OHB-607 (formerly TAK-607), is a proprietary, recombinant version of insulin-like growth factor 1 (IGF-1), the natural version of which is a key driver of fetal growth and development in-utero, and its binding protein, IGFBP-3. IGF-1 plays an important role in the development of the fetus. OHB-607 has been evaluated in both preclinical and clinical studies to treat Bronchopulmonary Dysplasia. A Phase II clinical trial showed a statistically significant shift toward milder Bronchopulmonary Dysplasia and a positive trend in reducing intraventricular hemorrhage (pre-specified secondary endpoints), with no significant safety signal observed. The company plans to restart the Phase IIb trial to evaluate 0HB-607 in Bronchopulmonary Dysplasia patients.

CHF5633: Chiesi Farmaceutici S.p.A.

Chiesi Farmaceutici is evaluating CHF5633 to treat Bronchopulmonary Dysplasia. It is the first fully synthetic surfactant enriched by peptide analogs of two human surfactant proteins. The drug is in the early clinical stage of development for Bronchopulmonary Dysplasia. Through the clinical success of porcine surfactant (Poractant alfa, Curosurf) in treating neonatal respiratory distress syndrome (RDS), Chiesi has established an impressive platform in neonatology. CHF5633 completed its evaluation in Phase II compared to Curosurf in treating preterm neonates with RDS. The drug is presently being evaluated in early clinical-stage development to treat BPD.

List of products to be continued in the report…

Bronchopulmonary Dysplasia Market Outlook

While prenatal steroids, surfactants, ventilators, and improved resuscitation protocols have increased the survival rate of premature infants, there has been little progress in protecting their not fully developed organs from the trauma of life-saving measures at birth, including supplemental oxygen and breathing machines.

The pipeline for Bronchopulmonary Dysplasia is currently limited, consisting of only one key asset, i.e., OHB607 (mecasermin rinfabate), an intravenous infusion being developed by Oak Hill. Other assets in development include Pneumostem (Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells) being developed by Medipost, AT-100 (Airway Therapeutics), AVR-48 (AyuVis), and CHF5633 (Chiesi Farmaceutici).

Oak Hill Bio plans to restart the Phase IIb study of the drug to treat Bronchopulmonary Dysplasia. The company states that the drug has the potential to be the first breakthrough in more than 30 years to improve outcomes for preterm infants. It will be the first-ever therapy to enter the US, EU, and JP market for the treatment of Bronchopulmonary Dysplasia and might bring a significant boost in the Bronchopulmonary Dysplasia market.

With all other drugs in the early stages of development, until now, OHB607 seems to be the most promising candidate in the clinical pipeline of Bronchopulmonary Dysplasia. The market is expected to react positively to OHB607, aiding it in solidifying its position as a leading therapy for this indication, as no other therapy has been able to pave its way to approval yet. We believe the expected approval of emerging therapy and the improving understanding of the disease due to advancing techniques will allow the market to rise at a significant rate.

According to the publisher, Bronchopulmonary Dysplasia 7MM is expected to change in the study period 2019-2032.

Key Findings

• The market size of Bronchopulmonary Dysplasia in seven major markets was USD 0.028 million in 2021, which is further expected to increase by 2032 at a Compound Annual Growth Rate (CAGR) of 66.2% for the study period (2019-2032)
• The expected Launch of potential therapies may increase market size in the coming years, assisted by an increase in the incident population of Bronchopulmonary Dysplasia.
• Upcoming therapies such as Oak Hill Bio's (OHB607) have the potential to create a significant positive shift in the Bronchopulmonary Dysplasia market size.
• The United States accounts for the largest market size of Bronchopulmonary Dysplasia, in comparison to EU5 (Germany, Italy, France, Spain, and the United Kingdom) and Japan.
• Among the EU5 countries, Germany and France had the highest market size with USD 0.002 million in 2021.

The United States Market Outlook

This section provides the total Bronchopulmonary Dysplasia market size and market size by therapies in the United States.

EU-5 Market Outlook

The total Bronchopulmonary Dysplasia market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan Market Outlook

The total Bronchopulmonary Dysplasia market size and market size by therapies in Japan are provided.

Bronchopulmonary Dysplasia Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the Bronchopulmonary Dysplasia market or expected to get launched in the market during the study period 2019-2032. The analysis covers the Bronchopulmonary Dysplasia market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows, the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Bronchopulmonary Dysplasia Development Activities

The report provides insights into different therapeutic candidates in phase II, and phase III stages also analyze key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Bronchopulmonary Dysplasia emerging therapies.

Reimbursement Scenario in Bronchopulmonary Dysplasia

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

Competitive Intelligence Analysis

The publisher performs competitively and market Intelligence analysis of the Bronchopulmonary Dysplasia market by using various competitive intelligence tools that include-SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

• The report covers the descriptive overview of Bronchopulmonary Dysplasia, explaining its etiology, signs and symptoms, pathophysiology, genetic basis, and currently available therapies.
• Comprehensive insight has been provided into the Bronchopulmonary Dysplasia epidemiology and treatment.
• Additionally, an all-inclusive account of both the current and emerging therapies for Bronchopulmonary Dysplasia is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
• A detailed review of the Bronchopulmonary Dysplasia market; historical and forecasted is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Bronchopulmonary Dysplasia market.

Report Highlights

• The robust pipeline with novel MOA and oral ROA and increasing incidence will positively drive the Bronchopulmonary Dysplasia market.
• The companies and academics are working to assess challenges and seek opportunities that could influence Bronchopulmonary Dysplasia R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• Major players are involved in developing therapies for Bronchopulmonary Dysplasia. The launch of emerging therapies will significantly impact the Bronchopulmonary Dysplasia market.
• Our in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Bronchopulmonary Dysplasia Report Insights

• Patient Population
• Therapeutic Approaches
• Bronchopulmonary Dysplasia Pipeline Analysis
• Bronchopulmonary Dysplasia Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Bronchopulmonary Dysplasia Report Key Strengths

• 11-Years Forecast
• The 7MM Coverage
• Bronchopulmonary Dysplasia Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

Bronchopulmonary Dysplasia Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers
• SWOT analysis

Key Questions Answered

Market Insights:

• What was the Bronchopulmonary Dysplasia market share (%) distribution in 2019 and how it would look like in 2032?
• What would be the Bronchopulmonary Dysplasia total market size as well as market size by therapies across the 7MM during the forecast period (2022-2032)?
• What are the key findings pertaining to the market across the 7MM and which country will have the largest Bronchopulmonary Dysplasia market size during the forecast period (2022-2032)?
• At what CAGR, the Bronchopulmonary Dysplasia market is expected to grow at the 7MM level during the forecast period (2022-2032)?
• What would be the Bronchopulmonary Dysplasia market outlook across the 7MM during the forecast period (2022-2032)?
• What would be the Bronchopulmonary Dysplasia market growth till 2032 and what will be the resultant market size in the year 2032?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

• What is the disease risk, burden, and unmet needs of Bronchopulmonary Dysplasia?
• What is the historical Bronchopulmonary Dysplasia patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
• What would be the forecasted patient pool of Bronchopulmonary Dysplasia at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Bronchopulmonary Dysplasia?
• Out of the above-mentioned countries, which country would have the highest incidence population of Bronchopulmonary Dysplasia during the forecast period (2022-2032)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2022-2032)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

• What are the current options for the treatment of Bronchopulmonary Dysplasia along with the approved therapy?
• What are the current treatment guidelines for the treatment of Bronchopulmonary Dysplasia in the US and Europe?
• What are the Bronchopulmonary Dysplasia marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
• How many companies are developing therapies for the treatment of Bronchopulmonary Dysplasia?
• How many emerging therapies are in the mid-stage and late stages of development for the treatment of Bronchopulmonary Dysplasia?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Bronchopulmonary Dysplasia therapies?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Bronchopulmonary Dysplasia and their status?
• What are the key designations that have been granted for the emerging therapies for Bronchopulmonary Dysplasia?
• What are the 7MM historical and forecasted market of Bronchopulmonary Dysplasia?

Reasons to Buy

• The report will help in developing business strategies by understanding trends shaping and driving Bronchopulmonary Dysplasia.
• To understand the future market competition in the Bronchopulmonary Dysplasia market and an Insightful review of the key market drivers and barriers.
• Organize sales and marketing efforts by identifying the best opportunities for Bronchopulmonary Dysplasia in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Organize sales and marketing efforts by identifying the best opportunities for the Bronchopulmonary Dysplasia market.
• To understand the future market competition in the Bronchopulmonary Dysplasia market.